A5288: MULTIOCTAVE, Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure

Study Location:

India

Topic:

HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT01641367?term=A5288&rank=1

IRB#:

IRB00043723

Coordinator:

Nishi Suryavanshi

Enrollment:

Closed

Trial Period:

Ongoing

The study is being done to:

test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the HIV in your blood to see which drugs might work best to lower your HIV infection.
see how well combinations of new anti-HIV drugs work to lower HIV infection
see if taking new anti-HIV drugs together is safe and tolerable
see if text messages improve people's anti-HIV drug-taking behavior (only at sites doing the adherence study)
in people taking certain combinations of anti-HIV drugs with an anti-TB drug, compare how these drugs act in the body
in Step 3, to see how people do after they stop having frequent clinic visits as part of a research study

HIV-1-infected males and females at non-US sites, aged ≥18 years, who have experience with or resistance to NRTIs, NNRTIs, and PIs, and are currently failing a PI-containing regimen.

Categories

Location
Topic

Clinical Trials

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More